HIKESHI-Related Hypomyelinating Leukodystrophy

HIKESHI-related hypomyelinating leukodystrophy is a very rare, inherited brain white-matter disease. It happens when both copies of a gene called HIKESHI do not work properly. The HIKESHI protein normally helps move the cell’s “heat-shock helper” proteins (HSP70s) into the nucleus to protect and organize other proteins, especially when cells are stressed (like during fever). When HIKESHI is missing or weak, oligodendrocytes (the cells that make myelin) cannot mature well, so the brain’s myelin is thin or under-formed (“hypomyelination”). That causes early-life motor delay, muscle tone problems, eye movement problems, feeding issues, and, in some children, worsening during fevers. Brain MRI shows diffuse hypomyelination. The condition is autosomal recessive. genecards.org+2Orpha+2

HIKESHI-related hypomyelinating leukodystrophy is a genetic brain white-matter disease where babies develop weak muscle tone, slow motor milestones, feeding difficulty, abnormal eye movements (nystagmus), and later stiff muscles with twisting postures (spastic–dystonic quadriplegia). MRI shows “hypomyelination,” meaning myelin—the insulation around nerve fibers—never forms properly rather than being lost later. The cause is pathogenic variants in the HIKESHI gene (also called C11ORF73), which encodes Hikeshi, a carrier that ferries HSP70 chaperone proteins into the nucleus during stress; without it, developing oligodendrocytes can’t mature and lay down myelin. Founder variants such as V54L have been reported (notably in Ashkenazi Jewish populations), and deterioration can be triggered by fever. There is currently no approved cure. PMC+3Nature+3Monarch Initiative+3

Under heat or cellular stress, HSP70 needs to move into the nucleus to protect DNA, proteins, and myelin-building programs. Hikeshi is the specialized nuclear import carrier that escorts HSP70 through the nuclear pore. When HIKESHI is defective, HSP70 can’t enter the nucleus on cue; protective stress responses misfire, SOX10 (a key myelin transcription factor) becomes unstable, oligodendrocytes stall, and myelin remains thin or absent—hence hypomyelination. Animal and cell models confirm that Hikeshi is essential for myelinogenesis and that pushing nuclear HSP70 can restart myelin programs. ScienceDirect+1

---

Other names

This disorder can be found in clinics and databases under these names (they all refer to the same disease family):

• HIKESHI-related hypomyelinating leukodystrophy (HHL)

• Hypomyelinating leukodystrophy due to Hikeshi deficiency

• C11ORF73-related autosomal recessive hypomyelinating leukodystrophy (older gene name)

• Hypomyelinating leukodystrophy 13 (HLD13) in some catalogs
  All of these labels indicate pathogenic variants in HIKESHI (formerly C11ORF73) with infantile-onset hypomyelination. deciphergenomics.org+3Orpha+3MalaCards+3

---

Types

There is no official set of subtypes yet, but doctors see a spectrum:

1. Classic infantile, severe form: early hypotonia, later spasticity/dystonia, feeding difficulty, eye movement problems, and diffuse hypomyelination on MRI. Some children worsen during fevers. PMC+1

2. Infantile with prominent ocular features: early nystagmus and optic atrophy alongside motor delay. MalaCards

3. Infantile with seizures/vermian atrophy: hypomyelination plus cerebellar vermis atrophy and epilepsy in some cases. Nature

4. Mechanistically “maturation-arrest” predominant: studies show oligodendrocytes fail to mature due to lost nuclear HSP70 support; this helps explain variable severity. PubMed

---

Causes

1. Biallelic HIKESHI mutations (autosomal recessive): the root cause; both gene copies carry pathogenic variants. Orpha

2. Missense variants (e.g., p.Val54Leu): specific amino-acid changes can strongly reduce function; V54L is recurrent in some groups. NCBI+1

3. Nonsense/frameshift variants: predicted loss of protein causes severe functional failure. MalaCards

4. Defective nuclear import of HSP70: HIKESHI normally ferries ATP-HSP70 into the nucleus during stress; loss blocks this rescue pathway. ScienceDirect

5. Oligodendrocyte maturation arrest: without nuclear HSP70, key myelin-program proteins are not protected, stalling myelin formation. PubMed

6. SOX10 instability: nuclear HSP70 normally shields SOX10 from degradation; instability impairs myelin-gene transcription. PubMed

7. Proteostasis stress during fever: heat stress increases demand for nuclear HSP70; deficiency explains clinical worsening after febrile illness. ScienceDirect+1

8. Endoplasmic reticulum (ER) redox imbalance: patient cells showed ER oxidoreductase changes (e.g., ERO1-Lα), adding stress to myelin biology. Nature

9. Abnormal interaction with FG-nucleoporins: HIKESHI interacts with nuclear pore proteins; disruption impairs transport under stress. genecards.org

10. Reduced HSP70 nuclear cycling at baseline: some data suggest import problems even without heat, adding chronic vulnerability. ResearchGate

11. Cell differentiation stress: oligodendrocyte differentiation itself requires HIKESHI/HSP70; failure intensifies hypomyelination. PubMed

12. Cerebellar susceptibility: cases show vermian atrophy, implying regional vulnerability beyond cerebrum. Nature

13. Mitochondrial/oxidative stress cross-talk: heat-shock systems often buffer oxidative injury; loss may tilt toward damage (mechanistic inference based on HSP biology). ScienceDirect

14. Protein-quality control overload: without nuclear HSP70, misfolded nuclear proteins accumulate, harming myelin gene expression. Wiley Online Library

15. Developmental timing: pathology emerges when rapid myelination is expected, magnifying impact of transport failure. PMC

16. Genetic background modifiers: different variants and backgrounds likely shape severity; founder effects (e.g., Ashkenazi V54L) highlight population factors. PMC

17. Inflammation triggers: infections can raise temperature and stress responses, unmasking functional deficits. PMC

18. Autophagy/lysosome traffic changes: experimental work suggests mislocalization patterns in variant proteins, hinting at clearance pathway strain. ResearchGate

19. Inadequate remyelination: animal studies show nuclear HSP70 promotes remyelination; loss may limit recovery after injury. PubMed

20. Global myelin-gene program disruption: combined SOX10 instability, ER stress, and proteostasis failure depress broad myelin pathways. PubMed+1

---

Symptoms

1. Slow motor development: delays in holding head up, sitting, or walking because white matter does not mature normally. MalaCards

2. Low muscle tone (early hypotonia): babies feel “floppy,” then many develop stiffness later. Pedneur

3. Stiff or tight muscles later (spasticity): legs may scissor or feel tight; this often follows the early floppy phase. MalaCards

4. Abnormal twisting or postures (dystonia): involuntary postures can appear with growth. PMC

5. Feeding difficulty and poor weight gain: weak suck, swallowing issues, and “failure to thrive” can occur. PMC

6. Eye movement problems (nystagmus): eyes may make small, quick movements; some children have vision pathway involvement. MalaCards

7. Optic atrophy: the nerve to the eye can be affected, lowering vision. MalaCards

8. Small head size (microcephaly) in some: head growth can lag. MalaCards

9. Seizures (some cases): epilepsy has been reported, especially with cerebellar changes. Nature

10. Poor coordination (ataxia): balance and coordination can be affected by cerebellar and white-matter issues. MalaCards

11. Worsening during fever: neurologic status can decline during or after high temperature. PMC

12. Speech delay or limited speech: white-matter injury can slow language skills. Pedneur

13. Swallowing trouble (dysphagia): increases risk of choking or aspiration. PMC

14. Contractures over time: tight joints can develop due to spasticity and reduced mobility. Pedneur

15. General developmental delay: combined motor, communication, and self-care delays are common. MalaCards

---

Diagnostic tests

A) Physical examination (bedside)

1. Developmental and neurologic exam: doctors check tone, reflexes, posture, and milestones to spot hypotonia, emerging spasticity/dystonia, and global delay typical of hypomyelinating disorders. Pedneur

2. Cranial nerve and eye exam: looks for nystagmus, optic atrophy signs, and tracking problems. MalaCards

3. Growth and nutrition assessment: head size, weight trends, and feeding efficiency are tracked because failure to thrive is common. PMC

4. Spasticity/contracture screening: modified Ashworth and range-of-motion checks help document disease impact and plan therapy. Pedneur

5. Cerebellar testing adapted for age: simple reach, posture, and sitting balance tasks can show ataxia features. MalaCards

B) Manual/functional tests (clinical tools)

6. Gross Motor Function Measure (GMFM) or age-adapted motor scales: structured observation of rolling, sitting, standing, and walking to quantify progress or decline. Pedneur

7. Feeding and swallow bedside screen: clinician observes suck–swallow–breath coordination to flag risk and need for a full study. PMC

8. Vision-tracking and fixation assessment: bedside tests for nystagmus, fixation, and pursuit guide referrals for formal vision tests. MalaCards

9. Tone and dystonia rating scales (e.g., Tardieu, BADS): help follow spasticity/dystonia over time for therapy planning. Pedneur

10. Functional Communication or Pediatric Evaluation of Disability Inventory (PEDI): tracks everyday abilities and care needs in progressive white-matter disease. Pedneur

C) Laboratory and pathological tests

11. Targeted or exome/genome sequencing of HIKESHI: confirms biallelic pathogenic variants; ClinVar lists recurrent p.Val54Leu. NCBI

12. Parental testing (segregation): shows both parents carry one variant each, supporting recessive inheritance. Orpha

13. Functional cell study (research/advanced centers): patient fibroblasts show impaired heat-shock–induced nuclear HSP70 import, a disease hallmark. Nature

14. Rule-out metabolic leukodystrophies: basic labs (e.g., very-long-chain fatty acids, amino/organic acids) to exclude other treatable white-matter diseases. (This is a differential-diagnosis step guided by leukodystrophy workups.) PanelApp

15. Infection workup during regressions: because fevers can worsen symptoms, tests identify and treat triggers quickly. PMC

D) Electrodiagnostic tests

16. Electroencephalogram (EEG): used when seizures are suspected or documented in the course of HIKESHI deficiency. Nature

17. Visual evoked potentials (VEP): can detect optic pathway dysfunction when optic atrophy or nystagmus is present. MalaCards

18. Brainstem auditory evoked responses (BAER): sometimes used to screen auditory pathways in leukodystrophies with broad white-matter involvement. PanelApp

E) Imaging tests

19. Brain MRI (core test): shows diffuse hypomyelination—white matter looks persistently immature across serial scans; patterns may include periventricular changes, and some cases show cerebellar vermis atrophy. PMC+2MalaCards+2

20. MR spectroscopy (when available): can show metabolic changes that support a white-matter disorder and help rule out alternatives. PanelApp

Non-pharmacological treatments (therapies & supports)

Because there is no approved disease-modifying drug, care is multidisciplinary.

1. Fever vigilance & fast fever control — Parents get a clear plan for temperature checks and early antipyretic/fluids at the first sign of illness; clinics provide low threshold for evaluation during infections. Purpose: lower risk of acute neurologic regressions seen after febrile episodes. Mechanism: avoids heat-stress surges that the HIKESHI/HSP70 pathway can’t buffer well. PMC

2. Intensive physical therapy (PT) — Daily, developmentally sequenced PT to maintain joint range, posture, and motor patterns; use gentle stretching, positioning, and task-specific training. Purpose: delay contractures, optimize function. Mechanism: neuroplasticity and muscle–tendon conditioning even when myelin is sparse. Cureus

3. Occupational therapy (OT) — Training in feeding, dressing, seating, and assistive device use; home modifications; caregiver body-mechanics. Purpose: reduce caregiver burden, increase participation. Mechanism: compensatory strategies harness preserved circuits and reduce spastic triggers. Cureus

4. Speech–language & swallow therapy — Early swallow studies; pacing, texture modification, thickened liquids if needed; augmentative and alternative communication (AAC). Purpose: reduce aspiration, support communication. Mechanism: safer biomechanics and neurodevelopmental stimulation despite dysmyelination. Cureus

5. Nutrition optimization — High-calorie, high-protein plans; micronutrient repletion; G-tube if aspiration/poor growth persists. Purpose: prevent failure to thrive. Mechanism: ensures energy for growth and rehab in a high-needs nervous system. Cureus

6. Orthotics & seating systems — AFOs, supportive seating, head/neck supports; standing frames to build bone density. Purpose: posture, contracture prevention, mobility safety. Mechanism: external alignment reduces spasticity triggers and pressure injury risk. Cureus

7. Vision/ophthalmology care — Treat strabismus; low-vision strategies; contrast-rich environments. Purpose: improve interaction and learning. Mechanism: compensates for nystagmus/visual pathway inefficiency found in hypomyelination. PMC

8. Respiratory hygiene — Chest PT, suction training, vaccines (influenza, pneumococcal), sleep studies if hypoventilation suspected. Purpose: cut infection admissions and hypoxic stress. Mechanism: preserves gas exchange and lowers febrile/inflammatory hits. Cureus

9. Spasticity-reducing modalities — Heat packs, hydrotherapy, stretching schedules, and serial casting as appropriate. Purpose: ease care, reduce pain. Mechanism: modulates reflex arcs and muscle spindle sensitivity non-pharmacologically. Cureus

10. Palliative & psychosocial support — Symptom control, goals-of-care, respite resources from early on. Purpose: improve quality of life across a rare, severe course. Mechanism: structured symptom relief and family support reduce crisis care. Cureus

11. Early-intervention programs — Government/NGO-based developmental services from infancy. Purpose: maximize developmental gains. Mechanism: enriched, repetitive sensory–motor input counters developmental risk. Cureus

12. Communication tech (AAC) — Switches, eye-gaze boards, or tablet-based AAC. Purpose: reduce frustration, enable learning/relationships. Mechanism: bypasses dysarthria/motor limits. Cureus

13. Caregiver emergency plan — Written action steps for fever, seizures, feeding issues, and dehydration. Purpose: shorten time to care in high-risk events. Mechanism: structured response for stress intolerance in HIKESHI deficiency. PMC

14. Thermoregulation precautions — Avoid overheating, hot environments, and prolonged exertion in heat. Purpose: minimize stress mis-handling. Mechanism: reduces demand for HSP70 nuclear import that cannot scale. ScienceDirect

15. Sleep optimization — Positioning, routines, and, if needed, non-drug measures for nocturnal spasticity. Purpose: neurodevelopment and caregiver resilience. Mechanism: restores synaptic homeostasis vital in dysmyelination. Cureus

16. Bone health measures — Weight-bearing, vitamin D/calcium adequacy, fracture prevention. Purpose: counter immobility osteoporosis. Mechanism: mechanotransduction from standing frames + nutrition. Cureus

17. Infection-control hygiene — Handwashing, sick-contact avoidance, prompt treatment of otitis/URIs. Purpose: fewer fevers = fewer regressions. Mechanism: prevents inflammatory/heat stress cascades. PMC

18. School/IEP planning — Individualized education plans with PT/OT/SLP embedded. Purpose: inclusive learning. Mechanism: accommodations for motor/visual limits. Cureus

19. Genetic counseling — For parents/family re: recurrence risk, carrier testing, community resources. Purpose: informed reproductive choices. Mechanism: autosomal recessive inheritance education. National Organization for Rare Disorders

20. Clinical-trial readiness — Register with leukodystrophy networks and natural-history studies; share MRI/genetics. Purpose: accelerate therapy development. Mechanism: enables researchers to test HIKESHI/HSP70-targeted strategies. ELAI International

---

Drug treatments

There is no FDA-approved drug that corrects HIKESHI function or cures HLD-13. Medications below are used off-label or on-label to manage spasticity, dystonia, seizures, and feeding complications. Always individualize dosing with your specialist.

1. Baclofen (oral) — A GABA_B agonist that reduces spinal reflex hyperexcitability to ease spasticity; typical start 5 mg 1–3×/day (pediatric dosing is weight-based), titrate slowly to effect while watching for sedation and hypotonia. Side effects: drowsiness, weakness, constipation; taper to avoid withdrawal. FDAaccessdata+1

2. Tizanidine — Central α2-agonist for spasticity; start low and titrate (e.g., 2 mg up to every 6–8 h), monitor liver enzymes and blood pressure; can help nocturnal spasms. Side effects: sedation, dry mouth, hypotension. FDAaccessdata+1

3. Diazepam — Benzodiazepine helpful for spasms/anxiety; carefully titrate (e.g., 0.12–0.8 mg/kg/day in divided pediatric doses). Side effects: somnolence, respiratory depression with other CNS depressants. FDAaccessdata+1

4. Dantrolene — Acts peripherally on skeletal muscle excitation–contraction coupling; consider for refractory spasticity; monitor hepatotoxicity; adult caps commonly 25–100 mg 3–4×/day (pediatric specialist dosing required). FDAaccessdata+1

5. OnabotulinumtoxinA (Botox) — Focal chemodenervation for targeted spastic muscles or sialorrhea protocols; injected by trained clinicians every ~12 weeks; monitor for diffusion weakness. FDAaccessdata+1

6. Clonazepam — For myoclonus or seizures (if present); tiny bedtime doses may also reduce nocturnal spasms; watch for sedation and dependence. FDAaccessdata+1

7. Levetiracetam — Broad-spectrum anti-seizure drug with favorable kinetics; pediatric dosing weight-based; monitor mood/behavioral changes. FDAaccessdata

8. Valproate — Broad anti-seizure option; monitor liver function and platelets; avoid in certain metabolic risks; dosing individualized. FDAaccessdata

9. Acid-suppression (e.g., PPI) — For reflux contributing to poor weight gain/aspiration risk; pediatric GI supervises dosing and duration; weigh infection/bone risks. Mechanism: reduces acid exposure to protect esophagus. (FDA labels vary by agent; use per-drug guidance). Cureus

10. Glycopyrrolate or Atropine drops (sialorrhea) — Reduce drooling that worsens skin breakdown/aspiration; dose cautiously to avoid constipation/urinary retention. (Use per label/consensus pathways.) Cureus

Additional agents sometimes considered by specialists (individualize; evidence in HLD-13 is limited): intrathecal baclofen pump, trihexyphenidyl (dystonia), gabapentin (neuropathic pain/tone), melatonin (sleep), oxcarbazepine/topiramate (seizures), prokinetics (feeding intolerance). FDAaccessdata

---

Dietary molecular supplements

Supplements don’t fix HIKESHI, but may support general neuro-nutrition when prescribed thoughtfully. Discuss all supplements with your team.

1. Vitamin D — Correct deficiency to support bone health in low mobility. Typical pediatric repletion per serum levels (e.g., 600–2000 IU/day, individualized). Mechanism: calcium homeostasis and bone mineralization. Cureus

2. Omega-3 (DHA/EPA) — May aid general neurodevelopment and reduce inflammation; dosing by weight/age. Mechanism: membrane fluidity and anti-inflammatory lipid mediators. Cureus

3. Vitamin B-complex (esp. B12, folate) — Treat deficiency states that worsen neurologic function; dosing guided by labs. Mechanism: methylation and axonal metabolism. Cureus

4. Coenzyme Q10 — Antioxidant support; pediatric dosing varies (e.g., ~5–10 mg/kg/day in divided doses). Mechanism: mitochondrial electron transport and redox buffering. Cureus

5. L-Carnitine — Consider if malnutrition/anticonvulsants reduce reserves; dose per weight. Mechanism: fatty-acid transport into mitochondria. Cureus

6. Creatine — May augment muscle energy stores for therapy sessions; dose under specialist guidance. Mechanism: phosphocreatine buffering. Cureus

7. N-acetylcysteine (NAC) — Precursor to glutathione; theoretical antioxidant support; mind GI side effects. Mechanism: redox balance. Cureus

8. Alpha-lipoic acid — Redox cofactor with antioxidant properties; pediatric data limited. Mechanism: mitochondrial enzyme support. Cureus

9. Probiotics — For GI comfort and feeding tolerance; choose clinically studied strains. Mechanism: microbiome–gut–brain axis. Cureus

10. Curcumin (standardized) — Anti-inflammatory adjunct in some neuro-rehab programs; monitor for interactions. Mechanism: NF-κB pathway modulation. Cureus

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved “immunity boosters” or stem-cell drugs for HIKESHI-HLD; avoid clinics advertising unproven “stem-cell cures.” Research directions include gene-therapy screening on brain-on-chip models, HSP70 nuclear import modulation, and hyperthermia-induced Hikeshi pathways in animals. Supportive care with vaccination and infection prevention remains the safest way to protect fragile myelin development. ELAI International+1

• Erythropoietin (EPO) has preclinical neuroprotective signals in myelin injury models but is not approved for HLD-13; use only in trials. Mechanism: oligodendrocyte support/anti-apoptotic pathways (experimental). Nature

• Heat-shock pathway enhancers (experimental) aim to increase nuclear HSP70 when Hikeshi is limited; not clinically available yet. ScienceDirect

• SOX10-stabilizing strategies (preclinical): because HSP70 protects SOX10 from degradation, drugs that mimic this could, in theory, promote myelin—currently research-only. PubMed
  (Other items under this heading are intentionally omitted because offering off-label “immune boosters” without evidence would be unsafe.)

---

Procedures/surgeries (when and why)

1. Gastrostomy tube (G-tube) — If unsafe swallow or persistent poor growth, a G-tube secures nutrition/meds and lowers aspiration risk. Cureus

2. Botulinum toxin chemodenervation — Targeted injections for focal spasticity/dystonia when oral meds underperform or cause sedation. FDAaccessdata

3. Intrathecal baclofen pump — For severe generalized spasticity with poor oral tolerance; requires surgical placement and ongoing titration. FDAaccessdata

4. Orthopedic procedures (e.g., tendon lengthening/hip containment) — When fixed contractures or subluxation limit care or pain relief. Cureus

5. Airway procedures (e.g., tracheostomy) — Reserved for severe airway protection or ventilation needs after multidisciplinary review. Cureus

---

Practical preventions

Genetic counseling & carrier testing (family planning); up-to-date vaccinations; prompt evaluation of fever; hand hygiene & sick-contact avoidance; safe swallowing plans; adequate calories/hydration; regular PT/OT/SLP; orthotics/seating checks; home temperature management (avoid overheating); written emergency plan for illness. National Organization for Rare Disorders+2PMC+2

---

When to see a doctor—right away

Seek urgent care for fever, new breathing difficulty, persistent vomiting/dehydration, new seizures, sudden loss of milestones, or signs of aspiration (coughing/choking with feeds). Arrange routine follow-up with neurology, rehab, nutrition, ophthalmology, and genetics, plus rapid access during viral seasons. PMC+1

---

What to eat & what to avoid

Eat: (1) calorie-dense, (2) protein-rich, (3) iron- and B-vitamin-adequate, (4) vitamin-D/ calcium-supportive foods, (5) fiber and fluids for bowel health.

Avoid/limit: (6) aspiration-prone textures unless cleared, (7) dehydrating routines during illness, (8) prolonged fasting before therapies, (9) heavy sedatives with alcohol/OTC antihistamines without clinician oversight, (10) overheating spicy meals if they provoke distress during fevers. Diet plans should be individualized by a pediatric dietitian. Cureus

---

FAQs

1) Is HIKESHI-HLD curable?
Not yet. Ongoing research targets Hikeshi/HSP70 nuclear import and oligodendrocyte maturation. PubMed

2) How is it inherited?
Autosomal recessive—both parents typically carry one nonworking copy. National Organization for Rare Disorders

3) Why do fevers cause setbacks?
The brain can’t mount normal HSP70 nuclear responses without Hikeshi, so heat stress overwhelms protective systems. ScienceDirect

4) What does the MRI show?
Diffuse hypomyelination (myelin never fully formed). PMC

5) Are there founder mutations?
Yes—V54L has been described with higher frequency in Ashkenazi Jews; others include Cys4Ser and P78S. ScienceDirect+2Nature+2

6) Could boosting HSP70 help?
Animal data suggest that driving nuclear HSP70 promotes oligodendrocyte differentiation, but human therapies are not ready. PubMed

7) Is gene therapy on the horizon?
A brain-on-chip model is being used to pre-test HIKESHI gene strategies—promising but early. ELAI International

8) What specialists should follow my child?
Neurology, physiatry/rehab, PT/OT/SLP, nutrition, ophthalmology, pulmonology as needed, and genetics. Cureus

9) Are seizures inevitable?
No; some patients do, others don’t. If present, standard anti-seizure medicines are used. PMC

10) Can Botox help?
Yes—onabotulinumtoxinA can relax focal overactive muscles and reduce drooling when used properly. FDAaccessdata

11) Is intrathecal baclofen an option?
For severe generalized spasticity unresponsive to oral meds—requires a pump and close follow-up. FDAaccessdata

12) What increases risk during illnesses?
Fever and systemic inflammation escalate cellular stress the Hikeshi system can’t handle. ScienceDirect

13) Why are SOX10 and oligodendrocytes mentioned so often?
Because SOX10 drives myelin-gene programs; nuclear HSP70 protects SOX10, enabling oligodendrocyte maturation. PubMed

14) Is this the same as all hypomyelinating leukodystrophies?
No—HIKESHI-HLD (HLD-13) is one genetically defined subtype with a distinct nuclear transport defect. National Organization for Rare Disorders

15) Where can families connect?
Leukodystrophy foundations and registries can guide services and trials; ask your clinic about regional networks. ELAI International

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 07, 2025.